Until now, Orbitrap-based profiling has only been used to compare two metabolomes (plasma and serum) of small-cell lung cancer (SCLC) patients undergoing treatment with standard chemotherapy (Wedge et al. 2011) and to characterize KRAS mutants in NSCLC cells (Brunelli et al. 2014). The gene discussed is KRAS; the disease is small cell lung carcinoma.